Literature DB >> 24592954

The PulmoSphere™ platform for pulmonary drug delivery.

Jeffry Weers1, Thomas Tarara.   

Abstract

Spray-dried PulmoSphere™ formulations comprise phospholipid-based small, porous particles. Drug(s) may be incorporated in or with PulmoSphere formulations in three formats: solution-, suspension-, and carrier-based systems. The multiple formats may be administered to the respiratory tract with multiple delivery systems, including portable inhalers (pressurized, metered-dose inhaler and dry-powder inhaler), nebulizers, and via liquid dose instillation in conjunction with partial liquid ventilation. The PulmoSphere platform (particles, formats, delivery systems) enables pulmonary delivery of a broad range of drugs independent of their physicochemical properties and lung dose. The engineered particles provide significant improvements in lung targeting and dose consistency, relative to current marketed inhalers.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24592954     DOI: 10.4155/tde.14.3

Source DB:  PubMed          Journal:  Ther Deliv        ISSN: 2041-5990


  14 in total

Review 1.  The Impact of Inspiratory Flow Rate on Drug Delivery to the Lungs with Dry Powder Inhalers.

Authors:  Jeffry Weers; Andy Clark
Journal:  Pharm Res       Date:  2016-10-13       Impact factor: 4.200

2.  Generation of High Concentrations of Respirable Solid-Phase Aerosols from Viscous Fluids.

Authors:  Xin Heng; Donovan B Yeates
Journal:  Aerosol Sci Technol       Date:  2018-07-30       Impact factor: 2.908

Review 3.  Physical stability of dry powder inhaler formulations.

Authors:  Nivedita Shetty; David Cipolla; Heejun Park; Qi Tony Zhou
Journal:  Expert Opin Drug Deliv       Date:  2019-12-13       Impact factor: 6.648

4.  Spray Dried Rugose Lipid Particle Platform for Respiratory Drug Delivery.

Authors:  Hui Wang; Mani Ordoubadi; Patrick Connaughton; Kellisa Lachacz; Nicholas Carrigy; Scott Tavernini; Andrew R Martin; Warren H Finlay; David Lechuga-Ballesteros; Reinhard Vehring
Journal:  Pharm Res       Date:  2022-04-01       Impact factor: 4.200

5.  Micro-fluidic Spray Freeze Dried Ciprofloxacin Hydrochloride-Embedded Dry Powder for Inhalation.

Authors:  Yingjie Chen; Shen Yan; Shengyu Zhang; Quanyi Yin; Xiao Dong Chen; Winston Duo Wu
Journal:  AAPS PharmSciTech       Date:  2022-08-02       Impact factor: 4.026

6.  Ciprofloxacin DPI: a randomised, placebo-controlled, phase IIb efficacy and safety study on cystic fibrosis.

Authors:  Henry L Dorkin; Doris Staab; Elisabeth Operschall; Jeff Alder; Margarita Criollo
Journal:  BMJ Open Respir Res       Date:  2015-12-02

Review 7.  Carriers for the targeted delivery of aerosolized macromolecules for pulmonary pathologies.

Authors:  Nashwa Osman; Kan Kaneko; Valeria Carini; Imran Saleem
Journal:  Expert Opin Drug Deliv       Date:  2018-07-26       Impact factor: 6.648

Review 8.  Inhaled Biologicals for the Treatment of Cystic Fibrosis.

Authors:  Valentina Sala; Alessandra Murabito; Alessandra Ghigo
Journal:  Recent Pat Inflamm Allergy Drug Discov       Date:  2019

Review 9.  Control of the Lung Residence Time of Highly Permeable Molecules after Nebulization: Example of the Fluoroquinolones.

Authors:  Julien Brillault; Frédéric Tewes
Journal:  Pharmaceutics       Date:  2020-04-23       Impact factor: 6.321

Review 10.  The Rationale and Evidence for Use of Inhaled Antibiotics to Control Pseudomonas aeruginosa Infection in Non-cystic Fibrosis Bronchiectasis.

Authors:  Rajiv Dhand
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2017-10-27       Impact factor: 2.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.